Sophia Danhof

Oberdürrbacher Street 6
Wuerzburg, BY 97080, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

Tailored strategies for improved control of CAR-T cells in multiple myeloma.

Tailored strategies for improved control of CAR-T cells in multiple myeloma.

Journal: Frontiers in immunology
Published: November 05, 2025

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Journal: HemaSphere
Published: August 06, 2025

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 27, 2025

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice.

Journal: Cell reports. Medicine
Published: December 05, 2024

Cellular Therapies for Multiple Myeloma: Engineering Hope.

Cellular Therapies for Multiple Myeloma: Engineering Hope.

Journal: Cancers
Published: October 15, 2024

Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies.

Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies.

Journal: Oncology research and treatment
Published: October 02, 2024

BCMA CAR-T cells in multiple myeloma-ready for take-off?

BCMA CAR-T cells in multiple myeloma-ready for take-off?

Journal: Leukemia & lymphoma
Published: November 24, 2023

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Journal: Communications biology
Published: July 03, 2023

Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.

Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.

Journal: Clinical and experimental medicine
Published: January 17, 2023

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells.

Journal: Haematologica
Published: May 02, 2022

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.

Journal: Leukemia
Published: November 30, 2021

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study.

The influence of baseline characteristics, treatment and depression on health-related quality of life in patients with multiple myeloma: a prospective observational study.

Journal: BMC cancer
Published: October 27, 2021
Showing 1-12 of 42

Last Updated: 09/26/2026